nach oben

Drugs

Erschienen in:

01.10.2008 | Adis Drug Profile

Transdermal Matrix Fentanyl Membrane Patch (Matrifen®)

In Severe Cancer-Related Chronic Pain

verfasst von: Philip I. Hair, Gillian M. Keating, Kate McKeage

Erschienen in: Drugs | Ausgabe 14/2008

Einloggen, um Zugang zu erhalten

Abstract

▲ The matrix fentanyl membrane patch is a new transdermal patch designed with a reduced drug load compared with established reservoir and matrix fentanyl patches.
▲ The drug is contained within a silicone matrix with a rate-controlling membrane designed to maintain constant serum fentanyl concentrations over the 72-hour application period.
▲ The matrix fentanyl membrane patch was equivalent to the reservoir fentanyl patch in terms of transdermal delivery of fentanyl, as demonstrated after both single (100 μg/h) and multiple (50 μg/h) applications by the peak serum fentanyl concentration and the area under the serum concentrationtime curve over 72 hours.
▲ In a randomized, nonblind, multicentre trial, the transdermal matrix fentanyl membrane patch was noninferior to standard opioid therapy (transdermal reservoir or matrix fentanyl patch or an oral opioid) in terms of analgesic efficacy over 30 days in patients with cancer-related chronic pain requiring long-term opioid use.
▲ The transdermal matrix fentanyl membrane patch was as well tolerated as standard opioid therapy; patient-rated tolerability scores for constipation, nausea, daytime drowsiness and sleep disturbance were similar between treatments.

The use of trade names is for product identification purposes only and does not imply endorsement.

Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999 May 15; 353(9165): 1695–700PubMedCrossRef

World Health Organization. WHO’s pain ladder [online]. Available from URL: http://www.who.int/cancer/palliative/painladder/en [Accessed 2007 Jan 23]

Mercadante S, Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 2005; 16 Suppl. 4: ivl32–5CrossRef

Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289–307PubMedCrossRef

Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Expert Working Group of the Research Network of the European Association for Palliative Care. Br J Cancer 2001 Mar; 84(5): 587–93PubMedCrossRef

Boddiger D. Fentanyl-laced street drugs “kill hundreds”. Lancet 2006 Aug 12; 368(9535): 569–70PubMedCrossRef

Janssen LP. Important drug warning [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2005/duragesic_ddL.pdf [Accessed 2007 Mar 6]

Davis MP. Management of cancer pain: focus on new opioid analgesic formulations. Am J Cancer 2006; 5(3): 171–82CrossRef

Marier JF, Lor M, Potvin D, et al. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol 2006 Jun; 46(6): 642–53PubMedCrossRef

10.

Hoy SM, Keating GM. Fentanyl Transdermal Matrix Patch (Durotep® MT Patch; Durogesic® D-Trans®; Durogesic® SMAT) in adults with cancer-related pain. Drugs 2008; 68(12): 1711–21PubMedCrossRef

11.

Marier JF, Lor M, Morin J, et al. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation. Br J Clin Pharmacol 2007 Jan; 63(1): 121–4PubMedCrossRef

12.

Matrifen®: summary of product characteristics (Sweden) [online]. Stockholm: Nycomed AB, 2006 Nov 16. Available from URL: http://www.lakemedelsverket.se [Accessed 2007 Jan 15]

13.

Kornick CA, Santiago-Palma J, Moryl N, et al. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003; 26(13): 951–73PubMedCrossRef

14.

Nycomed. Matrifen®: advanced technology [online]. Available from URL: http://www.matrifen.com [Accessed 2007 Jan 21]

15.

Nycomed. Comparative in-vitro release study. Roskilde: Nycomed, 2006. (Data on file)

16.

Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997 Jan; 53(1): 109–38PubMedCrossRef

17.

Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000 Jan; 38(1): 59–89PubMedCrossRef

18.

Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989 Jun; 70(6): 928–34PubMedCrossRef

19.

Takane H, Nosaka A, Wakushima H, et al. Rifampin reduces the analgesic effect of transdermal fentanyl [letter]. Ann Pharmacother 2005 Dec; 39(12): 2139–40PubMedCrossRef

20.

Hase I, Oda Y, Tanaka K, et al. I.V. fentanyl decreases the clearance of midazolam. Br J Anaesth 1997 Dec; 79(6): 740–3PubMedCrossRef

21.

Ahmedzai S. Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997; 13(5): 254–61PubMedCrossRef

22.

Wong JO, Chiu G-L, Tsao C-J, et al. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997; 35: 25–32PubMed

23.

Payne R. Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998 Apr; 16(4): 1588–93PubMed

24.

Kress HG, Von der Laage D, Hoerauf KH, et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage. Epub 2008 Jun

Titel: Transdermal Matrix Fentanyl Membrane Patch (Matrifen®)
In Severe Cancer-Related Chronic Pain
verfasst von: Philip I. Hair
Gillian M. Keating
Kate McKeage
Publikationsdatum: 01.10.2008
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 14/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868140-00005

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 14/2008

Raloxifene

Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Alvimopan

Use of Somatostatin Analogues in Obesity

Patients at High Risk of Invasive Fungal Infections

Doripenem